IMMUNOSUPPRESSANT MONITORING BY MALDI MASS SPECTROMETRY
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Mar 29, 2012
app pub date -
Sep 2, 2011
filing date -
Sep 3, 2010
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
The invention relates to therapeutic drug monitoring (TDM) by mass spectrometry, particularly to the monitoring of immunosuppressant levels in blood of patients with transplanted organs. A liquid phase extraction procedure reproducibly extracts the therapeutic drug molecules from whole blood and mass spectrometric analysis on MALDI instruments, with a matrix substance for highest sensitivity and special sample deposition procedure for a reproducible ionization of the therapeutic drug molecules. Suitable internal standard substances added to the blood in exact amounts ensure a correct absolute quantification. The method is particularly suitable for immunosuppressants belonging to the class of macrocyclic lactones (sirolimus, tacrolimus, everolimus) and cyclic polypeptides (cyclosporin A), and even works as a multiplex method for all four immunosuppressants simultaneously.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully